Leerink upgraded Quest Diagnostics (DGX) to Outperform from Market Perform with a price target of $174, up from $169. The firm notes its view ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback